Cancer Patient Assessment

Data were collected between March and June 2022 at a National Cancer Institute (NCI)–Designated Cancer Center in Southern California through an online survey. The intent of the cross-sectional study was to assess cannabis-related knowledge, attitudes, and behaviors among cancer survivors as well as their individual cancer experiences and related symptoms. A total of 5901 patients were invited to participate in the study, and 954 (16.2%) provided responses. A third-party company weighted the final analytic responses to ensure that the sample was representative of the cancer center’s patient population. The weighted sample size was 4807, representing the target population.